Rossler A, Netzl A, Lasrado N, Chaudhari J, Muhlemann B, Wilks S
Cell Rep. 2025; 44(1):115140.
PMID: 39754717
PMC: 11781863.
DOI: 10.1016/j.celrep.2024.115140.
Liu Y, Nie J
Vaccines (Basel). 2024; 12(11).
PMID: 39591159
PMC: 11598284.
DOI: 10.3390/vaccines12111256.
Zhang B, Fong Y, Fintzi J, Chu E, Janes H, Kenny A
Nat Commun. 2024; 15(1):7954.
PMID: 39261482
PMC: 11390939.
DOI: 10.1038/s41467-024-52348-9.
Tan C, Zhu F, Chia W, Young B, Yeoh A, Althaus T
Hlife. 2024; 1(1):26-34.
PMID: 38994526
PMC: 11238253.
DOI: 10.1016/j.hlife.2023.07.002.
Chang-Rabley E, van Zelm M, Ricotta E, Edwards E
Vaccines (Basel). 2024; 12(6).
PMID: 38932404
PMC: 11209597.
DOI: 10.3390/vaccines12060675.
Machine Learning to Identify Critical Biomarker Profiles in New SARS-CoV-2 Variants.
Schatz C, Knabl L, Lee H, Seeboeck R, von Laer D, Lafon E
Microorganisms. 2024; 12(4).
PMID: 38674742
PMC: 11052335.
DOI: 10.3390/microorganisms12040798.
Measuring Variant-Specific Neutralizing Antibody Profiles after Bivalent SARS-CoV-2 Vaccinations Using a Multivariant Surrogate Virus Neutralization Microarray.
Springer D, Holtl E, Pruger K, Puchhammer-Stockl E, Aberle J, Stiasny K
Vaccines (Basel). 2024; 12(1).
PMID: 38250907
PMC: 10818493.
DOI: 10.3390/vaccines12010094.
Development of a novel medium throughput flow-cytometry based micro-neutralisation test for SARS-CoV-2 with applications in clinical vaccine trials and antibody screening.
OReilly S, Kenny G, Alrawahneh T, Francois N, Gu L, Angeliadis M
PLoS One. 2023; 18(11):e0294262.
PMID: 38033116
PMC: 10688860.
DOI: 10.1371/journal.pone.0294262.
Validation of a SARS-CoV-2 Surrogate Neutralization Test Detecting Neutralizing Antibodies against the Major Variants of Concern.
Santos da Silva E, Servais J, Kohnen M, Arendt V, Staub T, The Con-Vince Consortium
Int J Mol Sci. 2023; 24(19).
PMID: 37834413
PMC: 10573711.
DOI: 10.3390/ijms241914965.
Explicit modeling of antibody levels for infectious disease simulations in the context of SARS-CoV-2.
Muller S, Paltra S, Rehmann J, Nagel K, Conrad T
iScience. 2023; 26(9):107554.
PMID: 37654471
PMC: 10466916.
DOI: 10.1016/j.isci.2023.107554.
Characterizing SARS-CoV-2 neutralization profiles after bivalent boosting using antigenic cartography.
Rossler A, Netzl A, Knabl L, Bante D, Wilks S, Borena W
Nat Commun. 2023; 14(1):5224.
PMID: 37633965
PMC: 10460376.
DOI: 10.1038/s41467-023-41049-4.
Potent pan huACE2-dependent sarbecovirus neutralizing monoclonal antibodies isolated from a BNT162b2-vaccinated SARS survivor.
Chia W, Tan C, Tan A, Young B, Starr T, Lopez E
Sci Adv. 2023; 9(30):eade3470.
PMID: 37494438
PMC: 10371021.
DOI: 10.1126/sciadv.ade3470.
A Multivariant Surrogate Neutralization Assay Identifies Variant-Specific Neutralizing Antibody Profiles in Primary SARS-CoV-2 Omicron Infection.
Springer D, Traugott M, Reuberger E, Kothbauer K, Borsodi C, Nageli M
Diagnostics (Basel). 2023; 13(13).
PMID: 37443672
PMC: 10341213.
DOI: 10.3390/diagnostics13132278.
Humoral Response after a Fourth Dose with mRNA-1273 in Healthcare Workers with and without a History of SARS-CoV-2 Infection and Previously Vaccinated with Two Doses of BBIBP-CorV Plus BNT162b2 Vaccine.
Gomez de la Torre J, Hueda-Zavaleta M, Caceres-DelAguila J, Muro-Rojo C, Cruz-Escurra N, Benites-Zapata V
Vaccines (Basel). 2023; 11(5).
PMID: 37242998
PMC: 10221616.
DOI: 10.3390/vaccines11050894.
Immunological imprinting: Understanding COVID-19.
Koutsakos M, Ellebedy A
Immunity. 2023; 56(5):909-913.
PMID: 37105169
PMC: 10113596.
DOI: 10.1016/j.immuni.2023.04.012.
Safety and immunogenicity of heterologous ChAdOx1-nCoV19 and BNT162b2 vaccination: A meta-analysis of the heterologous COVID-19 vaccination outcomes.
Hu Y, Wang Y, Shao T, Tang W, Hu K, Zhou Y
Vaccine. 2023; 41(18):3003-3010.
PMID: 37037708
PMC: 10060199.
DOI: 10.1016/j.vaccine.2023.03.056.
Hybrid Immunity to SARS-CoV-2 from Infection and Vaccination-Evidence Synthesis and Implications for New COVID-19 Vaccines.
Spinardi J, Srivastava A
Biomedicines. 2023; 11(2).
PMID: 36830907
PMC: 9953148.
DOI: 10.3390/biomedicines11020370.
Vaccine- and Breakthrough Infection-Elicited Pre-Omicron Immunity More Effectively Neutralizes Omicron BA.1, BA.2, BA.4 and BA.5 Than Pre-Omicron Infection Alone.
Santos da Silva E, Servais J, Kohnen M, Arendt V, Gilson G, Staub T
Curr Issues Mol Biol. 2023; 45(2):1741-1761.
PMID: 36826057
PMC: 9955496.
DOI: 10.3390/cimb45020112.
Competition of SARS-CoV-2 variants on the pandemic transmission dynamics.
Chen J, Gu C, Ruan Z, Tang M
Chaos Solitons Fractals. 2023; 169:113193.
PMID: 36817403
PMC: 9915129.
DOI: 10.1016/j.chaos.2023.113193.
Efficacy of an unmodified bivalent mRNA vaccine against SARS-CoV-2 variants in female small animal models.
Corleis B, Hoffmann D, Rauch S, Fricke C, Roth N, Gergen J
Nat Commun. 2023; 14(1):816.
PMID: 36781853
PMC: 9924835.
DOI: 10.1038/s41467-023-36110-1.
